Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies

Kim, Jon Jin, Shaw, Olivia, Martin, Chloe, Michaelides, George, Balasubramaniam, Ramnath, Sebire, Neil J., Mamode, Nizam, Dorling, Anthony, Vaughan, Robert and Marks, Stephen D. (2018) Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Pediatric Nephrology, 33 (1). pp. 167-174. ISSN 0931-041X

PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (766kB) | Preview


Introduction: We have previously shown that children who developed de novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) had greater decline in allograft function. We hypothesised that patients with complement-activating DSA would have poorer renal allograft outcomes. Methods: A total of 75 children developed DSA in the original study. The first positive DSA sample was subsequently tested for C1q and C3d fixing. The primary event was defined as 50% reduction from baseline estimated glomerular filtration rate and was analysed using the Kaplan–Meier estimator. Results: Of 65 patients tested, 32 (49%) and 23 (35%) tested positive for C1q and C3d fixing, respectively. Of the 32 C1q-positive (c1q+) patients, 13 (41%) did not show concomitant C3d fixing. The mean fluorescence intensity values of the original immunoglobulin G DSA correlated poorly with complement-fixing positivity (C1q: adjusted R2 0.072; C3d: adjusted R2 0.11; p < 0.05). C1q+ antibodies were associated with acute tubulitis [0.75 ± 0.18 (C1q+) vs. 0.25 ± 0.08 (C1q−) episodes per patient (mean ± standard error of the mean; p < 0.05] but not with worse long-term renal allograft dysfunction (median time to primary event 5.9 (C1q+) vs. 6.4 (C1q−) years; hazard ratio (HR) 0.74; 95% confidence ratio (CI) 0.30–1.81; p = 0.58]. C3d-positive (C3d+) antibodies were associated with positive C4d histological staining [47% (C3d+) vs. 20% (C3d−); p = 0.04] and with significantly worse long-term allograft dysfunction [median time to primary event: 5.6 (C3d+) vs. 6.5 (C3d−) years; HR 0.38; 95% CI 0.15–0.97; p = 0.04]. Conclusion: Assessment of C3d fixing as part of prospective HLA monitoring can potentially aid stratification of patients at the highest risk of long-term renal allograft dysfunction.

Item Type: Article
Uncontrolled Keywords: complement fixation,donor-specific antibodies,hla antibodies,prognosis,renal transplant,pediatrics, perinatology, and child health,nephrology ,/dk/atira/pure/subjectarea/asjc/2700/2735
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 14 Mar 2019 16:30
Last Modified: 24 Mar 2022 13:31
DOI: 10.1007/s00467-017-3772-7

Actions (login required)

View Item View Item